文献速递淋巴瘤造血干细胞移植与细胞治疗

新诊断套细胞淋巴瘤患者R-CHOP、阿糖胞苷和自体干细胞移植后硼替佐米维持治疗的随机II期HOVON试验结果

Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
PubMed 文献 · Br J Haematol · 2020-03-09

该随机II期研究评估了新诊断套细胞淋巴瘤患者在接受含利妥昔单抗诱导、大剂量阿糖胞苷和自体干细胞移植(ASCT)后,硼替佐米维持治疗与观察的疗效。135例合格患者中115例(85%)接受ASCT,60例(44%)随机分组。随机分组患者中,硼替佐米维持组5年EFS率为63%(95%CI 44-78%),5年OS率为90%(95%CI 72-97%);观察组5年PFS率为60%(95%CI 40-75%),OS率为90%(95%CI 72-97%)。结论:本II期研究未发现ASCT后硼替佐米维持治疗的阳性效果。

要点

  • 新诊断套细胞淋巴瘤患者接受R-CHOP、大剂量阿糖胞苷和ASCT后,硼替佐米维持治疗未显示获益。
  • 随机分组患者中,硼替佐米维持组与观察组的5年OS率均为90%。
  • 全组5年EFS率为51%,5年OS率为73%。

核心结论

  • 在本随机II期研究中,ASCT后硼替佐米维持治疗未显示阳性效果。

研究设计与样本

  • 随机II期研究,纳入新诊断套细胞淋巴瘤患者,诱导方案为3周期R-CHOP、2周期大剂量阿糖胞苷、BEAM和ASCT。
  • 135例合格患者中115例(85%)接受ASCT,60例(44%)随机分为硼替佐米维持组和观察组。

主要发现

  • 观察组5年PFS率为60%(95%CI 40-75%),5年OS率为90%(95%CI 72-97%)。

临床怎么用

  • 对于新诊断套细胞淋巴瘤患者,ASCT后硼替佐米维持治疗未显示生存获益,不建议常规使用。

局限性

  • 本研究为II期研究,样本量有限,随机分组患者仅60例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo-immuno regimen and ASCT with or without maintenance therapy with bortezomib. Induction consisted of three cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles high-dose cytarabine, BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT. Patients responding were randomised between bortezomib maintenance (1·3 mg/m2 intravenously once every 2 weeks, for 2 years) and observation. Of 135 eligible patients, 115 (85%) proceeded to ASCT, 60 (44%) were randomised. With a median follow-up of 77·5 months for patients still alive, 5-year event-free survival (EFS) was 51% (95% CI 42-59%); 5-year overall survival (OS) was 73% (95% CI 65-80%). The median follow-up of randomised patients still alive was 71·5 months. Patients with bortezomib maintenance had a 5-year EFS of 63% (95% CI 44-78%) and 5-year OS of 90% (95% CI 72-97%). The patients randomised to observation had 5-year PFS of 60% (95% CI, 40-75%) and OS of 90% (95% CI 72-97%). In conclusion, in this phase II study we found no indication of a positive effect of bortezomib maintenance after ASCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Doorduijn JK, Zijlstra JM, Lugtenburg PJ, et al. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020. PMID: 32150297. doi:10.1111/bjh.16567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。